Multiple SPC Applications Identified for Vildagliptin Products
GenericsWeb, the leader in established pharmaceutical patent analysis and searching, recently published an article based on its proprietary Pipeline Patent Intelligence that analyses opportunities in launching generic versions of the dipeptidyl peptidase-4 (DPP-4) inhibitor, Vildagliptin. Marketed by Novartis, Galvus® (Vildagliptin) and Eucreas® (Vildagliptin in combination with Metformin) are indicated for the treatment of Type II diabetes with reported global sales for Vildagliptin products of USD $391m in 2010. (PRWEB) December 05, 2011 The article by GenericsWeb highlights th
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 309
- Bankruptcy 44
- Business 133
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 608
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4